EGFR and lung cancer: In 2012, we summarized a review article that reported that each EGFR-mutated lung cancer cell line may employ a “preferred” mechanism upon acquisition of resistance to EGFR TKIs [11] (e.g., MET gene amplification in HCC827 cells and the induction of the epithelial-to-mesenchymal transition (EMT) phenotype in HCC4006 cells).